Please click the title(s) below to access the slides in each sharing session 请点击演讲标题获取PPT:

Session 1: Management, Human rights & labor, and Environment 管理体系、劳工、环境

• -PSCI最新进展
  -The PSCI and New Developments
• -如何着手建立管理体系
  -Demystifying Management Systems
• -EHS与GMP体系融合实践
  -Practical guidance on EHS & GMP System Integration
• -CXO企业EHS管理体系建设实践
  -The Initiative of EHS Systematic Management for a CXO Enterprise
• -PSCI 劳工和道德的最佳实践 - 法律法规追踪及商业道德的强化
  -Tracking on Laws/Regulations & Addressing Business Ethics
• -圆桌互动：劳工部分能力提升
  -Panel Session: Enhancement of Labor Performance
• -员工之声项目：数字化员工参与解决方案
  -Worker Voice Program: Digital Solutions for Worker Engagement
• -项目引进环保全过程管理实践
  -The Whole Process Environment Management Practice in Production Project Introduction
• -同心协力零碳雄心：成员公司范围三减排实践
  -Together to Reduce GHG Emissions

-------------------------------------------------
Session 2: Environment, Safety General, Process Safety Management, Industrial Hygiene 环境、安全总览、过程安全、职业卫生

• -制药行业抗生素耐药性管控趋势与思考
  -Trends on antibiotic resistance control in pharmaceutical industry
• -AMR控制标准嘉宾圆桌
  -Panel: Antibiotic Manufacturing Standard
• -泄漏与安全控制
  -Spill and Safe Containment
• -仓库安全总览
  -Warehouse General Safety
• -仓库安全：供应商案例分享
  -Warehouse Safety - Supplier Case Study
• -暴露监测和分析案例分享
  -Exposure Control and Monitoring – Case Study
• -活性药物管控策略——供应商案例分享
  -Potent Compounds and Control Strategy – Supplier Case Study

We are proud to announce that PSCI Treasurer Enric Bosch will be speaker at CPHI Barcelona this October. Enric will be speaking on the topic of Putting ESG into Practice: Creating Responsible Supply Chains via Common Audit Approaches.

We look forward to seeing you there!

The PSCI is delighted to announce that, starting today, PSCI training is accessible on Learnster🌟

Learnster is an e-learning platform that is:

• Interactive
• Easy to use
• High quality

The PSCI catalogue already includes many courses, covering topics such as fire protection, fair competition, biodiversity, freedom of association, communication of hazards, climate change, and more! Further courses, prepared by PSCI experts, will be released on a regular basis.

Watch this short video to learn more about Learnster.

If you have any questions, please email us.

The PSCI is a proud partner to Energize, a first-of-its-kind collaboration of 19 pharmaceutical companies focused on increasing the adoption of renewable electricity in the pharmaceutical supply chain. The program is designed to help pharma and healthcare suppliers learn about renewable electricity purchasing, explore the market, and engage in renewable energy procurement.

In the last 18 months, 472 leading suppliers have registered for the program, representing over 33 terawatt-hours of electricity demand. The program has already formed its first Power Purchase Agreement (PPA) buyers’ cohort to purchase renewable electricity collectively. The PPA buyers’ cohort includes 9 companies and intends to go to market together, resulting in a potential aggregate of 2 terawatt-hours (TWh) of electricity demand in Europe and North America.

• As suppliers engaged with the PSCI, you have the opportunity to participate in Energize’s education program on renewable electricity free of charge. The next series will begin in September and you can register today.

What will you learn in this education series?
The goal of this education series is to equip you and your team with a foundational understanding of the benefits and process of transitioning to renewable electricity as well as key considerations associated with methods for purchasing including:
• Onsite Solar
• Power Purchase Agreements
• Energy Attribute Certificates

Who should attend?
We advise a core team from your company, including a sustainability lead and/or procurement lead to attend this education series.

What are the benefits to attending?
To learn more about renewable energy and the options available to you to help meet you own decarbonization goals and those of your customers. Energize creates the unique opportunity for value chain partners to aggregate their electricity demand and gain access to renewable electricity purchasing option you otherwise wouldn’t have.

When does the series take place?
The series is offered from September to December in two different time slots to accommodate multiple time zones.

If you'd like to join the series, you can register your interest here.

If you have any questions, please contact energize@se.com.

About Energize
The Energize program is a supply chain renewables initiative designed and delivered by Schneider Electric Sustainability Business in partnership with the PSCI. Current sponsor companies include Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Charles River Laboratories, Chiesi Group, GSK, Johnson & Johnson, Merck (known as MSD outside the United States and Canada), Merck KGaA, Darmstadt, Germany, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Takeda, Teva, and UCB.

The PSCI is pleased to announce the publication of its updated Principles. The Principles underpin the work of PSCI, and form the basis of our mission. As such, we encourage all members, suppliers, and auditors to ensure they understand and are familiar with them.

The Principles have been in place, in their original form, since they were agreed by PSCI’s founding members in 2006. They were updated for the first time in December 2019. As part of our three-year periodic review, the PSCI has spent the last year in consultation with members, suppliers, partners, advisory panellists, and external stakeholders to refresh our foundational document.

Following this consultative process, all members were invited to vote to approve the new version of the Principles, which was formally adopted at the PSCI Spring Meeting on 23 May 2023.

The refreshed Principles take effect for members immediately. To ensure proper implementation, all members are now invited to start reflecting the changes in their policies, codes, processes, and practices. The first check-in will take place during the annual member calls in March 2024. All PSCI member companies are expected to have integrated the revised PSCI Principles by November 2024.

Significant changes to the Principles are:

• ‘Governance and Management Systems’ is now the first Principle, reflecting its foundational nature and impacting the other four sections (Ethics, Human Rights, Health & Safety, and Environment)
• Broader scope of the human rights section, now covering the rights of local communities and the commitment to conduct regular human rights risk assessments
• New clauses on establishing a culture of responsible practices, providing remediation, setting up grievance mechanisms, protecting products and quality, upholding the right to collection bargaining, supporting the wellbeing of workers, and conserving biodiversity
• Strengthened clauses on resource efficiency and climate change (covering suppliers' scope 3 emissions)

As ever, the Principles are made available freely and publicly to anyone with an interest in responsible supply chains for our sector. To view the Principles, visit them in our Resources library.

Any comments to the refreshed Principles, or their implementation, should be submitted to the Secretariat.

The Pharmaceutical Supply Chain Initiative (PSCI) Releases Position Paper on Sector’s Use of Horseshoe Crabs

• The PSCI - representing 75 of the world’s largest pharmaceutical companies - launches progressive position paper on the use of Horseshoe Crab blood in the industry
• Position paper addresses a range of issues to ensure sustainability and welfare of the Horseshoe Crab populations

22nd May 2023 – The Pharmaceutical Supply Chain Initiative (PSCI) just released a position paper on the use of Horseshoe Crabs in the pharmaceutical sector. The paper takes a progressive stance, noting the potential animal welfare and sustainability impacts of the use of Horseshoe Crab blood within the industry, and aims to encourage its member companies to minimize their use and seek out safe alternatives for their supply chains.

Horseshoe Crabs are an ancient group of crab species who have been around for more than 400 million years. Their blood has the remarkable property of indicating certain types of endotoxins. For this reason, it has been harvested by the medical and pharma industries to use as a test for these harmful compounds. Endotoxin testing using approved methods is a key demand of the regulators who authorize pharmaceutical development and manufacturing.

While this process does not require the death of the animal, there are still questions over possible animal welfare, biodiversity, and sustainability impacts from the collection of these materials from populations of wild crabs. Of the three affected species of Horseshoe Crabs across the US and Asia, one Asian species is listed as endangered, with concerns over the other Asian species where data is deficient.

The connection between the Horseshoe Crab species and the pharmaceutical sector highlights the importance of biodiversity for human health and acts an excellent example of interdependence between medicine and biodiversity. It also illustrates the complexity of biodiversity-related sourcing in a regulated industry.

However, it also emphasizes the need for the industry to take an active position, and so the PSCI has launched its progressive position paper on what it believes to be good practice for the use of Horseshoe Crab blood within the pharmaceutical industry.

“The PSCI is releasing this position paper to encourage our members to protect the endangered species, seek out alternatives to these materials, and to adopt an intentional approach to sourcing where it is remains necessary.

Our commitment is to work together now, to drive this transition towards a long-term sustainable position and to play our part in protecting these remarkable species.”
 
– A spokesperson for the PSCI
 
Representing 75 of the world’s largest pharmaceutical companies, the PSCI will encourage its members to commit to no further collection from endangered species, minimising the use of these materials, and sharing information to understand the animal welfare and conservation questions.

While this paper is not a membership requirement for the PSCI, it does outline the organisation’s views on good practice as it continues its commitment to the protection of all endangered species. It is important the industry has a strategy for reducing its dependence on Horseshoe Crab-derived products, and the PSCI is committed to working with its members to facilitate their progress and report the position across the whole industry.

Click here for the full position paper.

Please contact the PSCI at info@pscinitiative.org, or our Communications Manager, emma.wilkins@carnstone.com, if you have any questions or would like to learn more. 
 
About The PSCI 
Helping suppliers meet industry expectations. The PSCI was formed as a project between the 6 founding members in 2006 and was legally established in the United States as a non-profit membership organization in 2013. 
 
Our vision is for excellence in safety, environmental, and social outcomes for the whole of the global pharmaceutical and healthcare supply chain. Our purpose is to bring together members to define, establish, and promote responsible supply chain practices, human rights, environmental sustainability, and responsible business.
 
We achieve this through the PSCI Principles for Responsible Supply Chain Management. They are the blueprint for responsible practice, setting our expectations for five relevant topics: Ethics, Labor, Health & Safety, Environment, and Management Systems. 
 
Our strategy is based on the 6 strategic themes of: Leadership, Audit Partnering, Regional Presence, Supplier Learning, Innovation. 
www.pscinitiative.org

Follow us on:   
Twitter
LinkedIn